Biktarvy

GSK's ViiV says study shows its long-acting HIV shot as effective as Gilead's daily pill
GSK's ViiV says study shows its long-acting HIV shot as effective as Gilead's daily pill
Yahoo/Reuters
GSK
HIV
ViiV Healthcare
Gilead Sciences
Cabenuva
Biktarvy
Flag link:
Gilead reports 'very strong quarter' despite slipping Veklury sales
Gilead reports 'very strong quarter' despite slipping Veklury sales
Endpoints
Gilead Sciences
earnings
Biktarvy
Flag link:
GSK to get $1.25 bln to settle HIV drug patent row with Gilead
GSK to get $1.25 bln to settle HIV drug patent row with Gilead
Reuters
GSK
Gilead Sciences
HIV
Biktarvy
patents
Flag link:
Gilead Sciences : Study Data Of Biktarvy In People Living With HIV Show High Effectiveness
Gilead Sciences : Study Data Of Biktarvy In People Living With HIV Show High Effectiveness
NASDAQ
Gilead Sciences
Biktarvy
HIV
RWE
Flag link:
Gilead's Biktarvy build its case for long-term use with 4-year data showing lasting HIV suppression
Gilead's Biktarvy build its case for long-term use with 4-year data showing lasting HIV suppression
Endpoints
Gilead Sciences
Biktarvy
HIV
Flag link:
Gilead announces new data on Biktarvy for the treatment of HIV in Black Americans
Gilead announces new data on Biktarvy for the treatment of HIV in Black Americans
Pharmaceutical Business Review
Gilead Sciences
Biktarvy
HIV
Flag link:
GSK's plan to take over the HIV drug market hasn't worked out
GSK's plan to take over the HIV drug market hasn't worked out
BioPharma Dive
GSK
FDA
HIV
Dovato
Biktarvy
ViiV Healthcare
Gilead Sciences
Flag link:
Will Its HIV Lineup Save Gilead Sciences?
Will Its HIV Lineup Save Gilead Sciences?
Motley Fool
Gilead Sciences
HIV
Descovy
Biktarvy
Flag link:
Gilead Sciences Reports Improving Revenue in the 2nd Quarter
Gilead Sciences Reports Improving Revenue in the 2nd Quarter
Motley Fool
Gilead Sciences
earnings
Biktarvy
Flag link:
Pfizer's Xeljanz drops off top June TV spenders list—and Gilead's Biktarvy fills the void
Pfizer's Xeljanz drops off top June TV spenders list—and Gilead's Biktarvy fills the void
Fierce Pharma
AbbVie
Humira
Gilead Sciences
Biktarvy
Truvada
Pfizer
Xeljanz
television ads
DTC ads
Flag link:
Gilead Sciences’ Biktarvy shows high efficacy in HIV-1 study
Gilead Sciences’ Biktarvy shows high efficacy in HIV-1 study
Pharmaceutical Business Review
Gilead Sciences
Biktarvy
HIV-1
HIV
Flag link:
4 Biggest HIV Drugs of 2024: Which Stocks Are Poised to Profit?
4 Biggest HIV Drugs of 2024: Which Stocks Are Poised to Profit?
Motley Fool
HIV
Gilead Sciences
Biktarvy
GSK
Triumeq
Genvoya
Tivicay
Flag link:
GSK takes billion-dollar drug fight with Gilead to top AIDS meeting
GSK takes billion-dollar drug fight with Gilead to top AIDS meeting
Yahoo/Reuters
GSK
Gilead Sciences
HIV
AIDS
Dolutegravir
lamivudine
Biktarvy
Flag link:
GlaxoSmithKline's next-generation HIV battle against Gilead is already taking a toll on growth
GlaxoSmithKline's next-generation HIV battle against Gilead is already taking a toll on growth
Fierce Pharma
GSK
HIV
Biktarvy
Gilead Sciences
Triumeq
Tivicay
Flag link:
Gilead Receives Positive Opinion From CHMP on Combination HIV Drug Biktarvy
Gilead Receives Positive Opinion From CHMP on Combination HIV Drug Biktarvy
CP Wire
Gilead Sciences
Biktarvy
HIV
Flag link:
Gilead Receives Positive Opinion From CHMP on Combination HIV Drug Biktarvy
Gilead Sciences
Biktarvy
HIV
Flag link:
Gilead: Did Biktarvy Kill The Sell Thesis?
Gilead: Did Biktarvy Kill The Sell Thesis?
Seeking Alpha
Gilead Sciences
Biktarvy
HIV
Kite Pharma
Flag link:
3 Blockbuster Drug Launches to Watch In 2018
3 Blockbuster Drug Launches to Watch In 2018
Motley Fool
drug launches
Gilead Sciences
HIV
Biktarvy
Alnylam
Sanofi
Patisiran
Epidiolex
GW Pharma
Flag link:
12 blockbusters: The surging list of $1B-plus drugs rolling out on the market this year might surprise you
12 blockbusters: The surging list of $1B-plus drugs rolling out on the market this year might surprise you
Endpoints
drug launches
Hemlibra
Roche
Biktarvy
Gilead Sciences
Ozempic
Novo Nordisk
Erleada
JNJ
Shingrix
GSK
Patisiran
Alnylam
Sanofi
Epidiolex
GW Pharma
Aimovig
Amgen
Novartis
lanadelumab
Shire
Elagolix
AbbVie
Steglatro
Pfizer
Merck
Sublocade
Indivior
Flag link:
5 Drugs That Are Critical for Gilead Sciences' Future
5 Drugs That Are Critical for Gilead Sciences' Future
Motley Fool
Gilead Sciences
Biktarvy
Yescarta
selonsertib
filgotinib
Epclusa
Flag link:

Pages